SCHEDULE: State Street Discloses 5.1% Stake in Twist Bioscience

State Street Corporation has reported a 5.1% beneficial ownership stake in Twist Bioscience Corp, holding over 3 million common shares.

Summary

• State Street Corporation has filed a Schedule 13G, indicating beneficial ownership in Twist Bioscience Corp.
• The filing reports an aggregate beneficial ownership of 3,089,063 shares of common stock.
• This represents 5.1% of the class of securities.
• State Street Corporation holds shared voting power over 2,882,170 shares and shared dispositive power over all 3,089,063 shares.
• The filing was made by State Street Corporation as a parent holding company, with several investment adviser subsidiaries identified as acquiring the securities, including SSGA Funds Management, Inc. and State Street Global Advisors entities.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership by an institutional investor and does not contain information that would inherently drive a positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• The disclosure of a significant institutional stake by State Street Corporation, a major financial institution, could be viewed as a vote of confidence in Twist Bioscience Corp.

Negatives

• This filing is a standard disclosure of ownership and does not inherently contain negative financial or operational information about the issuer.

Risks

• This filing does not detail specific risks related to Twist Bioscience Corp's operations or financial health. It is a disclosure of beneficial ownership.

Future Outlook

Schedule 13G filings are for reporting current beneficial ownership and do not typically include forward-looking statements or guidance from the issuer or the reporting entity regarding the issuer's future performance.

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing reflects a standard institutional investment by a major asset manager, State Street Corporation, in a biotechnology company, Twist Bioscience Corp. Such disclosures are common for large institutional investors managing diverse portfolios, indicating their passive stake in publicly traded companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by State Street Corporation may be viewed positively by existing shareholders as it signals institutional confidence and liquidity.
• Management: The presence of a large institutional investor like State Street could imply increased scrutiny or engagement, though the filing explicitly states the investment is not for influencing control.

Key Dates

Keywords

Twist Bioscience, State Street, 13G, beneficial ownership, common stock, institutional investment, biotechnology, synthetic biology